3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation

Inclusion Criteria

• •1. Common to both sub-studies (A and B)
• •* Renal transplant patient aged between 18 and 75.
• •* Patient who received a first or second renal graft
• •* Immunosuppressive treatment consisting of an anti-calcineurin \[cyclosporine (trough levels: 150\<T0\<300)\], or tacrolimus (trough levels: 8\<T0\<12), mycophenolate mofetil and corticosteroids.
• •* Patient who benefited from a screening renal biopsy 3 months after the graft
• •* Patient who gave their informed consent
• •* Patient affiliated to a social security scheme or being a beneficiary of such a scheme
• •2. Specific to sub-study A
• •* Presence of "borderline" inflammatory infiltrates on the screening biopsy at 3 months as defined by the Banff classification 2013:
• •* Absence of vascular lesions (v0) and:
• •* tubulitis regardless of its significance (t1-3) with minimum interstitial infiltrate (i0-i1) OR
• •* interstitial infiltrates (i2-3) without significant tubulitis (≤ t1)
• •3. Specific to sub-study B Absence of significant inflammatory infiltrates (i0-1 and t0) on the screening biopsy at 3 months